Are there any specific technologies that are more useful to have together? Click here to view the entire series.
What Makes a Good CRO for Bioanalysis? Click here to view the entire series.
Dawn Dufield, Ph.D. and Dominic Warrino, Ph.D. discuss their approach to ligand binding assays (LBAs) and hybrid mass spectrometry (Hybrid LC-MS/MS) in this 11-part video series. What Makes a Good CRO for Bioanalysis? Are there any specific technologies that are more useful to have together? What is a…
In the scientific field, the often neglected fifth sense, the sense of smell, contributes to broadening our understanding of various phenomena, particularly in the field of biomarkers.Here, we will guide you along our lines of thought on the importance of our olfactory sense, and how it contributes to scientific exploration…
For researchers and professionals working in the biopharmaceutical industry, an upcoming Bioanalysis Zone Panel Discussion will offer a unique opportunity to stay informed about the latest advancements in quantitative analysis techniques. Research projects can only succeed when selecting the appropriate biopharmaceutical quantification technique. Staying…
In the complex and dynamic bioanalytical landscape of antibody-drug conjugate (ADC) services, where often time is critical and every research dollar counts, hybrid technology is quickly emerging as a game-changer. Hybrid offers a spectrum of advantages that redefine traditional approaches to bioanalytical ADC drug development. At the forefront…
November 15
- November 17
For years, Dawn Dufield, PhD and I have been doing our best to get the word out (via as many venues as possible) about KCAS’s unique expertise with hybrid LC-MS/MS. This year’s upcoming EBF meeting in Barcelona is just such an opportunity, and one we are very much looking…
With recent guidance released from the FDA, there are changes for PKs (Pharmacokinetics) and ADCs (Antibody Drug Conjugates) that must be clearly understood before making decisions for your drug product testing. ADCs combine the target specificity of monoclonal antibodies with the…
Dom and John discuss the role early non-clinical bio analysis plays in your project, why it is important, how it has changed over the years, and what might be next for this growing part of the industry. To view/listen to the episode of “the Weekly Bioanalysis” click the…
Anyone who has been following KCAS for any amount of time has likely heard us discuss the advantages of Hybrid LC-MS/MS for the bioanalysis of large molecules. As pioneers in the technology for many years, KCAS has become a strong proponent of working with our customers to demonstrate the…
With the extensive advances in technologies like CRISPR and CAR-T, cell and gene therapy has grown to become a viable way for treating Cancer as well as other diseases. Our team has over 100+ years of collective expertise in molecular services using qPCR and ddPCR for support of…
Dawn Dufield, PhD, Senior Director of Biopharmaceutical LC-MS/MS Services at KCAS Bio, has been invited to lead a workshop discussion session on Lipidomics at an upcoming Gordon Research Conference from August 7-12 in Newry, ME. The event will be a week long conference highlighting recent developments in standardization,…